Lisa Astor | Authors


Lifileucel Continues to Show Durable Responses in Advanced Melanoma

June 06, 2021

With further follow-up, lifileucel (LN-144) continued to show durable responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed on multiple therapies, including prior anti–PD-1/PD-L1 therapy

Positive Efficacy Data Found With Lifileucel TIL Therapy for Pretreated Advanced Melanoma

April 11, 2021

Lifileucel (LN-144), the tumor-infiltrating lymphocyte therapy, showed a positive objective response rate with the median duration of response not yet reached after more than 28 months of follow-up in patients with advanced melanoma.

ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer

March 20, 2021

An update from the phase 3 ARIEL4 trial presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer supports the continued use of rucaparib in patients with BRCA-mutant relapsed advanced ovarian cancer, based on progression-free survival and response data.